Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 14/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053258 | 0.84 | SLC6A9 (0.41) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL4545309 | 0.81 | SLC6A9 (0.43) | SLC6A9KCNH2SLC6A5KMT2ACYP3A4 | |
| SCHEMBL2687456 | 0.81 | SLC6A9 (0.48) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL1048043 | 0.81 | SLC6A9 (0.46) | SLC6A9KCNH2SLC6A5KMT2ACYP3A4 | |
| SCHEMBL15104500 | 0.80 | SLC6A9 (0.42) | SLC6A9KCNH2SLC6A5CYP3A4WDR5 | |
| SCHEMBL1052817 | 0.79 | SLC6A9 (0.48) | SLC6A9KCNH2SLC6A5KMT2ACYP3A4 | |
| SCHEMBL1054079 | 0.79 | SLC6A9 (0.41) | SLC6A9KCNH2SLC6A5KMT2ACYP3A4 | |
| SCHEMBL15104549 | 0.79 | SLC6A9 (0.41) | SLC6A9KCNH2SLC6A5KMT2ACYP3A4 | |
| SCHEMBL4545308 | 0.77 | SLC6A9 (0.44) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL15104522 | 0.76 | SLC6A9 (0.42) | SLC6A9KCNH2SLC6A5CYP3A4WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454240-A1 | GLYCINE TRANSPORTER INHIBITORS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| WO-2011007899-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | SLC6A5, SLC1A2, SLC18A2 | SLC6A9 5/4885KCNH2 1410/4885SLC6A5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.